Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers
    11.
    发明申请
    Piperidinyl Pyrimidine Amides As KV7 Potassium Channel Openers 审中-公开
    哌啶基嘧啶酰胺作为KV7钾通道开放剂

    公开(公告)号:US20130150391A1

    公开(公告)日:2013-06-13

    申请号:US13808355

    申请日:2011-06-20

    摘要: The present invention relates to compounds of Formula (I) as described herein or a pharmaceutically acceptable salt thereof, pharmaceutical composition comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof and methods of treating, or manufacture of a medicament to treat, a disease, disorder, or condition of the central nervous system, including bipolar disorder, depressive disorders, anxiety disorders, cognitive disorders, pain disorders, urogentital disorder, and epilepsy, among the other diseases, disorders or conditions discussed herein as mono-therapy or in combination with another active pharmaceutical ingredient.

    摘要翻译: 本发明涉及本文所述的式(I)化合物或其药学上可接受的盐,包含式(I)化合物或其药学上可接受的盐的药物组合物和治疗或制造治疗, 其中包括双相情感障碍,抑郁障碍,焦虑障碍,认知障碍,疼痛障碍,泌尿功能障碍和癫痫在内的其他疾病,疾病或病症中的疾病,病症或状况, 与另一种活性药物成分组合。

    Difluoromethylene aromatic ethers as inhibitors of glycine transport
    12.
    发明授权
    Difluoromethylene aromatic ethers as inhibitors of glycine transport 失效
    作为甘氨酸转运抑制剂的二氟亚甲基芳香醚

    公开(公告)号:US06710071B2

    公开(公告)日:2004-03-23

    申请号:US10219572

    申请日:2002-08-15

    IPC分类号: A61K31198

    摘要: This invention relates to a series of difluoromethylene aromatic ethers of the formula wherein ring A and X and Y are defined as in the specification, that exhibit activity as glycine transport inhibitors, their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their use for the enhancement of cognition and the treatment of the positive and negative symptoms of schizophrenia and other psychoses in mammals, including humans.

    摘要翻译: 本发明涉及一系列环丙烯环A的二氟亚甲基芳香醚,X和Y如说明书中所定义,其表现出作为甘氨酸转运抑制剂,其药学上可接受的盐,含有它们的药物组合物及其增强用途的活性 的认知和治疗哺乳动物,包括人类的精神分裂症和其他精神病的正面和负面症状。